Man Group plc Invests $7.16 Million in Sarepta Therapeutics, Inc. $SRPT

Man Group plc acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, HoldingsChannel.com reports. The firm acquired 398,144 shares of the biotechnology company’s stock, valued at approximately $7,155,000.

Other large investors also recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 214.2% during the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after buying an additional 3,671 shares during the period. Great Lakes Advisors LLC bought a new position in Sarepta Therapeutics in the 1st quarter valued at about $224,000. Guggenheim Capital LLC lifted its position in Sarepta Therapeutics by 33.5% during the second quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 11,497 shares during the last quarter. First Trust Advisors LP lifted its position in Sarepta Therapeutics by 59.2% during the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after acquiring an additional 233,391 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in Sarepta Therapeutics by 7.1% during the second quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock worth $1,972,000 after acquiring an additional 7,665 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. Finally, Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Trading Down 3.4%

Shares of SRPT stock opened at $20.86 on Friday. Sarepta Therapeutics, Inc. has a fifty-two week low of $14.68 and a fifty-two week high of $25.32. The stock’s fifty day moving average price is $17.73 and its two-hundred day moving average price is $18.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The company has a market cap of $2.20 billion, a PE ratio of -7.19, a P/E/G ratio of 0.31 and a beta of 0.23.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business’s revenue for the quarter was down 34.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 earnings per share. Equities analysts predict that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.